Ken Song, Candid Therapeutics CEO
September 9, 2024 09:00 AM EDT
Financing
Startups
China

In­vestors pour $370M+ in­to Ken Song's au­toim­mune biotech af­ter his Rayze­Bio suc­cess

Kyle LaHucik

Senior Reporter

Ken Song knows how to step on the gas ped­al.

His new com­pa­ny, called Can­did Ther­a­peu­tics, emerged from stealth on Mon­day morn­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times